Recent data releases from Novavax and Johnson & Johnson on coronavirus disease 2019 (COVID-19) vaccines show efficacy, but there remains some concern over new variants that have recently become more prevalent. Protein-based coronavirus 2019 (COVID-19) vaccine candidate NVX-CoV2373, from Novavax, has reported phase 3 findings showing 89.3% efficacy in prevention of COVID-19 in participants from the UK. Johnson & Johnson (J&J) announced today its JNJ-78436735 COVID-19 vaccine was 85 percent effective in preventing severe disease across all regions studied—28 days after vaccination. Source: HCP Live 30/1/21